---
layout: post
title: "康缘药业：收到枣柏安神颗粒临床试验批准通知书"
date: 2022-04-14 15:59:25 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.600557" data-code="600557|1|1" data-code2="600557|1|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.600557&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 600557_0" data-code="K 600557|1|1" data-code2="K 600557|1|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>康缘药业(600557)4月14日晚间公告，公司近日收到国家药监局签发的枣柏安神颗粒《药物临床试验批准通知书》，同意开展用于肝血不足、虚热内扰所致的慢性失眠症的临床试验。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204142343541872>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)